Barrie Weisman, MD in Lincoln, NH - Allergy & Immunology

Barrie Weisman, MD is a Allergy & Immunology physician based in Lincoln, New Hampshire. Barrie Weisman is licensed to practice in New Hampshire (license number 3926) and his current practice location is 67 Flume Rd, Lincoln, New Hampshire. He can be reached at his office (for appointments etc.) via phone at (603) 745-8603.

NPI number for Barrie Weisman is 1033118468 and his current mailing address is Po Box 865, Lincoln, New Hampshire. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1033118468.

Contact Information

	Barrie Weisman, MD
	67 Flume Rd, Lincoln, NH 03251
	(603) 745-8603
	Not Available

Physician's Profile

Full Name	Barrie Weisman
Gender	Male
Speciality	Allergy & Immunology
Location	67 Flume Rd, Lincoln, New Hampshire
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1033118468
Provider Enumeration Date: 07/18/2005
Last Update Date: 06/10/2022

Medical Identifiers

Medical identifiers for Barrie Weisman such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1033118468	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207K00000X	Allergy & Immunology	3926 (New Hampshire)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Barrie Weisman is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Barrie Weisman, MD Po Box 865, Lincoln, NH 03251-0865 Ph: (603) 991-6197	Barrie Weisman, MD 67 Flume Rd, Lincoln, NH 03251 Ph: (603) 745-8603

News Archive

Cardiovascular disease impact varies according to age, gender, other factors

Cardiovascular disease deaths have declined in the last 25 years, but the effect of America's No. 1 killer varies greatly based on gender, age, location and type, according to a study reported in Circulation: Journal of the American Heart Association.

Proteo's Elafin recommended for orphan drug status in Europe

The Committee for Orphan Medical Products (COMP) of the European Medicines Agency (EMEA) has issued a recommendation granting orphan drug status to Proteo's drug candidate Elafin for the treatment of esophagus carcinoma. The orphan drug status will become effective upon ratification of this recommendation by the European Commission.

Novel respiratory antibiotic Cethromycin, shown to be effective against Anthrax

Advanced Life Sciences Holdings has announced that its novel respiratory antibiotic, Cethromycin, was shown to be effective in preventing inhalation anthrax infection.

God will control my asthma

Research shows that patients' belief in God influences how likely they are to be adherent to asthma medication.

Two genetic rearrangements may trigger 5 to 7% of breast cancers

Researchers at the University of Michigan Comprehensive Cancer Center have discovered two cancer-spurring gene rearrangements that may trigger 5 to 7 percent of all breast cancers.

Barrie Weisman, MD - Allergy & Immunology in Lincoln, NH